Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Long-term treatment duration and safety of axatilimab among patients with chronic graft-versus-host disease in AGAVE-201

Carrie Kitko, Amandeep Salhotra, Mi Kwon, Zhenyi Xue, Valkal Bhatt, John Galvin, Patrick Hardesty, Silvia Mosher, Daniel Wolff

Blood (2025) 146 (Supplement 1): 6010.

https://doi.org/10.1182/blood-2025-6010

Published: 2025

Journal Articles

Grade I acute graft-vs-host disease: Treat or not?

Blood (2025) 146 (Supplement 1): 2461.

https://doi.org/10.1182/blood-2025-2461

Published: 2025

Journal Articles

Vorinostat for GVHD prophylaxis in children, adolescents, and young adults (AYA) shows low incidence of acute GVHD and relapse with encouraging overall survival after allogeneic hematopoietic cell transplantation (HCT): A multisite, nonrandomized clinical trial

Blood (2025) 146 (Supplement 1): 2451.

https://doi.org/10.1182/blood-2025-2451

Published: 2025

Journal Articles

Bone marrow next generation sequencing minimal residual disease (NGS-MRD) positivity pre-allogeneic hematopoietic cell transplantation (HCT) predicts outcomes for patients with B-cell acute lymphoblastic leukemia (B-ALL): A planned analysis from the ptctc ONC1401 trial

Amanda Johnson, Yuxin Zhao, Xi Qiao, J. Gregory Dolan, Karely Van Thiel Berghuijs, Julie-An Talano, Carrie Kitko, Sonali Chaudhury, Christopher Dvorak, Nahal Lalefar, Nancy Bunin, Neena Kapoor, Eric Anderson, Alice Bertaina, Allyson Flower, Michael Pulsipher, Hisham Abdel-Azim

Blood (2025) 146 (Supplement 1): 511.

https://doi.org/10.1182/blood-2025-511

Published: 2025

Journal Articles

Naïve Helper T-Cell and Regulatory T- and NK-Cell Subsets Are Associated with Pediatric Chronic Graft-Versus-Host Disease: Results of the ABLE / PBMTC 1202 Study

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-139031

Published: 2020

Journal Articles

Outcomes of Non-Myeloablative HLA-Haploidentical Bone Marrow Transplant with Thiotepa and Post-Transplant Cyclophosphamide in Children and Adults with Severe Sickle Cell Disease, a Phase II Trial: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC 2 )

Adetola A. Kassim, MDMS, Josu de la Fuente, Ali Debsan Alahmari, MBBS, MD MNAMS, Michael J. Eckrich, MD MPH, Rabi Hanna, MD, Nathalie Dhedin, MD, Biljana N. Horn, MD, Vandy Black, MDMSc, Roseane V Gouveia, Adriana Seber, MDMS, Belinda Pinto Simões, MD PhD, Thalita Cristina de Mello Costa, MD, Renato Guerino-Cunha, Carmem M. S. Bonfim, MDPhD, Roberto Luiz da Silva, Nelson Hamerschlak, MD PhD, Juliana Folloni Fernandes, MD, Michael Kent, MDBS, Satya Prakash Yadav, MBBS, MD, Erfan Nur, MDPhD, Mohsen Alzahrani, Ben Carpenter, PhD, William Tse, MD, Maria Isabel, Hemalatha G Rangarajan, MD, Ibrahim Ahmed, MD, Adeseye Michael Akinsete, MBBS, Courtney D. Fitzhugh, MD, Kathryn A. Culos, PharmD, Leena Karnik, FRCPath, MRCP, James Connelly, MD, Carrie Kitko, MD, Jennifer Andrews, MDMSc, Karina L Wilkerson, NP, MSN, Robert Brodsky, Tatsuki Koyama, Michael R. DeBaun, MD MPH

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-141771

Published: 2020

Journal Articles

Increased Incidence of New-Onset Diabetes Mellitus Type II Following Haploidentical Bone Marrow Transplant with Post-Transplant Cyclophosphamide for Sickle Cell Disease

Dilan A Patel, MD, Josu de la Fuente, Michael Matheney, MD, Leena Karnik, FRCPath, MRCP, Heidi Chen, PhD, Katie S. Gatwood, PharmD, Kathryn A. Culos, PharmD, Karina L Wilkerson, NP, MSN, Michael T. Byrne, DO, Salyka M. Sengsayadeth, MD, Stacey Ann Goodman, MD, Bhagirathbhai Dholaria, MBBS, Bipin N. Savani, MD, Wichai Chinratanalab, MD, Reena Jayani, MD, Jim Connelly, MD, Carrie Kitko, MD, Brian G. Engelhardt, MD, Adetola A. Kassim, MDMS

Blood (2020) 136 (Supplement 1): 20.

https://doi.org/10.1182/blood-2020-143039

Published: 2020

Journal Articles

Efficacy of Methoxsalen Sterile Solution in Conjunction with the Therakos ® Cellex ® Photopheresis System in Pediatric Patients with Steroid-Refractory Acute GvHD: Interim Analysis

Carrie Kitko, MD, Stefania Gaspari, MD, Henri Boodée

Blood (2019) 134 (Supplement_1): 4524.

https://doi.org/10.1182/blood-2019-124061

Published: 2019

Journal Articles

Next Generation Sequence Minimal Residual Disease (NGS-MRD) Predicts Outstanding Event Free Survival (EFS) Regardless of Hematopoietic Cell Transplantation (HCT) Preparative Approach or Graft Alpha/Beta Depletion in Children with Acute Lymphoblastic Leukemia (ALL)

Hisham Abdel-Azim, Christopher C. Dvorak, MD, Nancy Bunin, MD, Mark C. Walters, MD, Julie-An Talano, MD, Eric Jon Anderson, MD, Jemily Malvar, MS, May Al Jassani, Sonali Chaudhury, MBBS,MD, Mitchell S Cairo, MD, Carrie Kitko, MD, Allison P. Jacob, Dimitri S. Monos, PhD, Leung Wing, MD PhD, Michael A. Pulsipher, MD

Blood (2019) 134 (Supplement_1): 4624.

https://doi.org/10.1182/blood-2019-131706

Published: 2019

Journal Articles

The MAGIC Algorithm Probability (MAP): A Novel Laboratory Biomarker for the Response to Treatment of Acute Graft-Versus-Host Disease

Blood (2019) 134 (Supplement_1): 367.

https://doi.org/10.1182/blood-2019-122011

Published: 2019

Journal Articles

Serial Biomarker Monitoring Early after HCT Identifies Different Risks for Relapse and Graft-Vs-Host Disease

Blood (2018) 132 (Supplement 1): 356.

https://doi.org/10.1182/blood-2018-99-111200

Published: 2018

Journal Articles

Chemokines: a novel chronic GVHD target

Carrie Kitko, John E. Levine

Blood (2018) 131 (15): 1636–1638.

https://doi.org/10.1182/blood-2018-02-829101

Published: 2018

Journal Articles

Prognostic Value of TGFβ at Diagnosis of Chronic GvHD

Rima M Saliba, PhD, Carrie Kitko, MD, Pavan Reddy, MD, John M. Magenau, MD, Attaphol Pawarode, Steven Goldstein, Daniel R. Couriel, MD

Blood (2014) 124 (21): 5875.

https://doi.org/10.1182/blood.V124.21.5875.5875

Published: 2014

Journal Articles

Pneumocystis Jirovecii Pneumonia In Recipients Of Autologous Hematopoietic Stem Cell Transplantation: A 10-Year Cohort Study

Kadee J Raser, M.S., PA-C, Gregory A. Yanik, MD, John M. Magenau, M.D., Steven C. Goldstein, MD, Attaphol Pawarode, Carrie Kitko, M.D., John E. Levine, M.D., M.S., David Hanauer, M.S., M.D., Daniel R. Couriel, MD

Blood (2013) 122 (21): 3372.

https://doi.org/10.1182/blood.V122.21.3372.3372

Published: 2013

Journal Articles

An Algorithm Combining Clinical Characteristics and Day 7 Biomarker Concentrations Predicts Future Graft-Versus-Host Disease Following Related Donor Hematopoietic Cell Transplantation

Andrew C. Harris, M.D., James L.M. Ferrara, M.D., D.Sc., Thomas M. Braun, Ph.D., Daniel R. Couriel, M.D., Sung W. Choi, M.D., Carrie Kitko, M.D., Steven Goldstein, John M. Magenau, M.D., Sophie Paczesny, M.D., Ph.D, Attaphol Pawarode, Pavan Reddy, M.D., Gregory A. Yanik, Austin Taylor, James Connelly, M.D., Craig A. Byersdorfer, M.D., Ph.D., John E. Levine, M.D., M.S.

Blood (2012) 120 (21): 463.

https://doi.org/10.1182/blood.V120.21.463.463

Published: 2012

Journal Articles

Targeting Histone Deacetylases As a New Strategy for Graft Versus Host Disease Prevention

Blood (2012) 120 (21): 740.

https://doi.org/10.1182/blood.V120.21.740.740

Published: 2012

Journal Articles

Outcome of Transplantation for Acute Leukemia in Down Syndrome

Blood (2012) 120 (21): 1991.

https://doi.org/10.1182/blood.V120.21.1991.1991

Published: 2012

Journal Articles

Impact of immune modulation with in vivo T-cell depletion and myleoablative total body irradiation conditioning on outcomes after unrelated donor transplantation for childhood acute lymphoblastic leukemia

Blood (2012) 119 (25): 6155–6161.

https://doi.org/10.1182/blood-2012-01-405795

Published: 2012

Journal Articles

Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies

Blood (2011) 118 (15): 4258–4264.

https://doi.org/10.1182/blood-2011-06-358010

Published: 2011

Includes: Supplemental data

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation with Clofarabine/Busulfan × 4 (CloBu4) Conditioning Exhibits Significant Anti-Tumor Activity In Non - Remission Hematologic Malignancies, Especially In AML

Shin Mineishi, MD, John Magenau, MD, Hiromi Tobai, MD, Attaphol Pawarode, MD, Edward M. Peres, MD, Pavan Reddy, MD, Carrie Kitko, MD, Sung Choi, MD, Harry P Erba, MD, PhD, Lisa Kujawski, MD, Gregory Yanik, MD, James Ferrara, MD, John E. Levine, MD, MS

Blood (2010) 116 (21): 35.

https://doi.org/10.1182/blood.V116.21.35.35

Published: 2010

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Long-term treatment duration and safety of axatilimab among patients with chronic graft-versus-host disease in AGAVE-201

Grade I acute graft-vs-host disease: Treat or not?

Vorinostat for GVHD prophylaxis in children, adolescents, and young adults (AYA) shows low incidence of acute GVHD and relapse with encouraging overall survival after allogeneic hematopoietic cell transplantation (HCT): A multisite, nonrandomized clinical trial

Bone marrow next generation sequencing minimal residual disease (NGS-MRD) positivity pre-allogeneic hematopoietic cell transplantation (HCT) predicts outcomes for patients with B-cell acute lymphoblastic leukemia (B-ALL): A planned analysis from the ptctc ONC1401 trial

Naïve Helper T-Cell and Regulatory T- and NK-Cell Subsets Are Associated with Pediatric Chronic Graft-Versus-Host Disease: Results of the ABLE / PBMTC 1202 Study

Outcomes of Non-Myeloablative HLA-Haploidentical Bone Marrow Transplant with Thiotepa and Post-Transplant Cyclophosphamide in Children and Adults with Severe Sickle Cell Disease, a Phase II Trial: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC 2 )

Increased Incidence of New-Onset Diabetes Mellitus Type II Following Haploidentical Bone Marrow Transplant with Post-Transplant Cyclophosphamide for Sickle Cell Disease

Efficacy of Methoxsalen Sterile Solution in Conjunction with the Therakos ® Cellex ® Photopheresis System in Pediatric Patients with Steroid-Refractory Acute GvHD: Interim Analysis

Next Generation Sequence Minimal Residual Disease (NGS-MRD) Predicts Outstanding Event Free Survival (EFS) Regardless of Hematopoietic Cell Transplantation (HCT) Preparative Approach or Graft Alpha/Beta Depletion in Children with Acute Lymphoblastic Leukemia (ALL)

The MAGIC Algorithm Probability (MAP): A Novel Laboratory Biomarker for the Response to Treatment of Acute Graft-Versus-Host Disease

Serial Biomarker Monitoring Early after HCT Identifies Different Risks for Relapse and Graft-Vs-Host Disease

Chemokines: a novel chronic GVHD target

Prognostic Value of TGFβ at Diagnosis of Chronic GvHD

Pneumocystis Jirovecii Pneumonia In Recipients Of Autologous Hematopoietic Stem Cell Transplantation: A 10-Year Cohort Study

An Algorithm Combining Clinical Characteristics and Day 7 Biomarker Concentrations Predicts Future Graft-Versus-Host Disease Following Related Donor Hematopoietic Cell Transplantation

Targeting Histone Deacetylases As a New Strategy for Graft Versus Host Disease Prevention

Outcome of Transplantation for Acute Leukemia in Down Syndrome

Impact of immune modulation with in vivo T-cell depletion and myleoablative total body irradiation conditioning on outcomes after unrelated donor transplantation for childhood acute lymphoblastic leukemia

Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies

Allogeneic Hematopoietic Stem Cell Transplantation with Clofarabine/Busulfan × 4 (CloBu4) Conditioning Exhibits Significant Anti-Tumor Activity In Non - Remission Hematologic Malignancies, Especially In AML

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only